Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ICHOR HOLDINGS, LTD.ICHR · Entity 4529 | Director | May 15, 2024 | May 17, 2024 |
| LAM RESEARCH CORPLRCX · Entity 1467 | Chief Legal Officer & SVP | December 19, 2019 | December 23, 2019 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ICHOR HOLDINGS, LTD.
Report date May 15, 2024 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.0001SEC Table I · non-derivative | Direct | 28,325 |
Reported balance
After 2024-05-15 transaction · row 1
1 source rowRow 1 · 2024-05-15 · Grant · Acquired 3,923 · Balance 28,325 F1: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 9, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of an RSU grant, representing the right to receive Ordinary Shares of Ichor Holdings, Ltd. The RSU vests in full on May 9, 2025.
LAM RESEARCH CORP
Report date December 19, 2019 · Filed December 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,084 |
Reported balance
After 2019-12-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-12-19 · Sale · Disposed 3,831 · Balance 32,084 F1: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $287.804 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person. F2: Amount reported includes shares subject to unvested Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person contributed LRCX common stock to an exchange fund in exchange for shares of the exchange fund. The LRCX common stock was valued at $287.804 per share for the purpose of determining the number of shares of the exchange fund issuable to the reporting person.
F2: Amount reported includes shares subject to unvested Restricted Stock Units.
Protagonist Therapeutics, Inc
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,825 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 2,695 · Balance 7,825 F1: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.18 · Expires 2036-01-02 | Direct | 3,762 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 3,762 · Balance 3,762 F2: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date.
F2: The stock option vests in 12 equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2010 Filed Dec 8, 2010 20:01 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 3,213 | $50.00 | $160,650.00 |
DisclosureSEC source: 0001447149-10-000006 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,972 Read SEC document |
| October 28, 2010 Filed Nov 1, 2010 21:20 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | SaleCommon Stock | 7,207 | $44.76 | $322,585.32 |
DisclosureSEC source: 0001447149-10-000005 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,185 Read SEC document |
| June 15, 2010 Filed Jun 16, 2010 18:10 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 2,139 | $42.51 | $90,928.89 |
DisclosureSEC source: 0001447149-10-000004 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,986 Read SEC document |
| March 15, 2010 Filed Mar 16, 2010 17:10 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 2,139 | $32.68 | $69,902.52 |
DisclosureSEC source: 0001447149-10-000003 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,125 Read SEC document |
| February 05, 2010 Filed Feb 9, 2010 19:33 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 18,774 | $0.00 | $0.00 |
DisclosureSEC source: 0001447149-10-000002 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,264 Read SEC document |
| January 15, 2010 Filed Jan 19, 2010 17:13 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 2,320 | $36.82 | $85,422.40 |
DisclosureSEC source: 0001447149-10-000001 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,490 Read SEC document |
| September 29, 2009 Filed Oct 2, 2009 23:01 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | Tax withholdingCommon Stock | 1,787 | $33.57 | $59,989.59 |
DisclosureSEC source: 0001447149-09-000003 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,810 Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:16 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantStock Option (right to buy) · Derivative | 38,658 | $20.21 Strike: $20.21 | $781,278.18 |
DisclosureSEC source: 0001447149-09-000002 · primary_doc.xml · derivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,658 Underlying: Common Stock · 38,658 shares Expires 2014-02-26 F1 · derivative.exercise_date: 100% of the option will vest and become exercisable on 2/26/11. Read SEC document |
| February 26, 2009 Filed Mar 2, 2009 23:16 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 15,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001447149-09-000002 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,463 Read SEC document |
| February 06, 2009 Filed Feb 9, 2009 22:45 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001447149-09-000001 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Read SEC document |
| October 27, 2008 Filed Oct 28, 2008 00:24 UTC | LAM RESEARCH CORP LRCX · Entity 1467 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001447149-08-000002 · primary_doc.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · VP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.